Internet Archive Scholar

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes

Kieren J Mather, Robert V Considine, LaTonya Hamilton, Niral A Patel, Carla Mathias, Wendy Territo, Adam G Goodwill, Johnathan D Tune, Mark A Green, Gary D Hutchins
2018 Journal of Clinical Endocrinology and Metabolism  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (812.4 kB)
https://web.archive.org/web/20200311085214/https://scholarworks.iupui.edu/bitstream/handle/1805/17273/Mather_2018_combination.pdf;jsessionid=09DBB131E0B34F3368E8841C322A9DE8?sequence=1

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL. The file type is application/pdf.

It is unclear if effects of glucagon-like peptide-1 (GLP-1) and clinically available GLP-1 agonists on the heart occur at clinical doses in humans, possibly contributing to reduced cardiovascular disease risk.
doi:10.1210/jc.2018-00712 pmid:30020461 pmcid:PMC6126889 fatcat:5owfw4yz4fhshhvcf7hrwqlzm4
Citation

Kieren J Mather, Robert V Considine, LaTonya Hamilton, Niral A Patel, Carla Mathias, Wendy Territo, Adam G Goodwill, Johnathan D Tune, Mark A Green, Gary D Hutchins. "Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes." Journal of Clinical Endocrinology and Metabolism 103.9 (2018) 3456-3465